SBFM News & Events

Sunshine Biopharma announced the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex. Anastrozole is a highly prescribed non-steroidal aromatase inhibitor. It works by lowering estrogen levels in the body to slow down or reverse the growth of specific breast tumors. Anastrozole is standard care for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma. The Company anticipates that its Anastrozole will be ready to ship to pharmacies before the end of 2026.

Sunshine Biopharma announces the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto.

Sunshine Biopharma announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication. The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical viral enzyme responsible for suppression of the human immune system, making Coronavirus infections life-threatening.